Table: q1_q4_2022_prescription_drugs_intro_to_market , manufacturer_name like I*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

manufacturer_name	ndc_number	drug_product_description	date_introduced_to_market	wac_at_introduction	marketing_pricing_plan_description	marketing_pricing_plan_non_public_indicator	estimated_number_of_patients	breakthrough_therapy_indicator	priority_review_indicator	acquisition_date	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	general_comments	supporting_documents
Immunocore Commercial LLC	80446040101	Injection: 100 mcg/0.5 mL solution in a single-dose vial	2022-02-11	18760.0000	KIMMTRAK will be promoted by our commercial field teams to healthcare professionals and payers to educate them on our product. We will use various means of promotion including in-office visits, virtual meetings, ad campaigns, and digital marketing. Pricing was established by a comprehensive analysis to reflect the drug’s value to patients within our indicated population and the healthcare providers who treat them.	None	400	1	1	None	None	None	None	There are roughly 800-1000 metastatic uveal melanoma patients diagnosed and living in the U.S.  Approximately half of these patient are HLA-A-0201 positive making them eligible for KIMMTRAK	None
ImmunoGen, Inc.	72903085301	ELAHERE 100 mg/20 mL	2022-11-28	6220.0000	None	1	5200	None	1	None	None	None	None	None	None
Ingenus Pharmaceuticals, LLC	50742048401	Bortezomib Injection 3.5mg/vial	2022-05-02	800.0000	Ingenus prices their products based on the current market conditions along with a number of variables. All of these product specific variables are entered into a pricing model and pricing is determined. Some examples ( not all ) are cost of goods, profit share, freight costs, product volume, customer specific volumes, the COT/channels the specific product is sold in, rebates, chargebacks, contractual obligations. These factors vary product by product and aren’t all applicable in every case.	None	32500	None	None	None	None	None	None	As a manufacturer, Ingenus does not estimate the number of patients that may be prescribed our products. We manufacturer volume based on an estimated market share and/or usages provided by our customers. Our manufactured volumes are based on national level data and we do not break these estimates down to a patient or state level. Acquisition is not applicable.	None
Ingenus Pharmaceuticals, LLC	50742034001	Pemetrexed 100mg Injection	2022-05-25	160.0000	Ingenus does not plan to promote Pemetrexed Injection to physicians or other health professionals. The product will be sold to wholesalers and specialty distributors. Ingenus prices their products based on the current market conditions along with a number of variables. All of these product specific variables are entered into a pricing model and pricing is determined. Some examples ( not all ) are cost of goods, profit share, freight costs, product volume, customer specific volumes, the COT/channels the specific product is sold in, rebates, chargebacks, contractual obligations. These factors vary product by product and aren’t all applicable in every case.	None	25000	None	None	None	None	None	None	As a manufacturer, Ingenus does not estimate the number of patients that may be prescribed our products. We manufacturer volume based on an estimated market share and/or usages provided by our customers. Our manufactured volumes are based on national level data and we do not break these estimates down to a patient or state level. The patient number provided is a based on the number of patients covered by the drug indication. Acquisition is not applicable. The WAC per vial price is below the threshold, however when course of therapy is considered, the total WAC would be above the threshold.	None
Ingenus Pharmaceuticals, LLC	50742034101	Pemetrexed 500mg Injection	2022-05-25	800.0000	Ingenus does not plan to promote Pemetrexed Injection to physicians or other health professionals. The product will be sold to wholesalers and specialty distributors. Ingenus prices their products based on the current market conditions along with a number of variables. All of these product specific variables are entered into a pricing model and pricing is determined. Some examples ( not all ) are cost of goods, profit share, freight costs, product volume, customer specific volumes, the COT/channels the specific product is sold in, rebates, chargebacks, contractual obligations. These factors vary product by product and aren’t all applicable in every case.	None	25000	None	None	None	None	None	None	As a manufacturer, Ingenus does not estimate the number of patients that may be prescribed our products. We manufacturer volume based on an estimated market share and/or usages provided by our customers. Our manufactured volumes are based on national level data and we do not break these estimates down to a patient or state level. The patient number provided is a based on the number of patients covered by the drug indication. Acquisition is not applicable.	None